{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:23:03Z","timestamp":1793856183863,"version":"4.6.1"},"reference-count":54,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recently, the impressive efficacy of JAK\u2010inhibitors (JAK\u2010I) in alopecia areata (AA) has been described in several studies; however, to date, there is limited information on the safety of JAK\u2010I in AA patients. For this reason, on 18 August 2022, a systematic review was performed to collect the premarketing and postmarketing data on the safety of JAK\u2010I in patients treated for AA, evaluating for each molecule the reported adverse events (AEs) in indexed literature and their frequency. The keywords \u2018alopecia areata\u2019 AND \u2018Jak\u2010inhibitors OR Janus\u2010kinase Inhibitors\u2019 were searched on PubMed, Embase and Cochrane databases.<\/jats:p><jats:p>Of 407 studies retrieved, 28 papers met the requirements and were used in our review, including five RCTs and 23 case series; overall, 1719 patients were included, and the safety of 6 JAK\u2010I was assessed (baricitinib, brepocitinib, deuruxolitinib, ritlecitinib, ruxolitinib and tofacitinib). Systemic JAK\u2010I were well\u2010tolerated, most of the AEs were mild, and the withdrawal rate for AEs was very low and inferior to placebo in controlled studies (1.6% vs. 2.2%). Laboratory abnormalities represented 40.1% of AEs associated with oral JAK\u2010I, which mostly included the rise in cholesterol, transaminase, triglycerides, creatine phosphokinase (CPK) and sporadic cases of neutro\/lymphocytopenia. The remaining AEs involved the respiratory tract (20.8%), the skin (17.2%), the urogenital (3.8%), or the gastroenterological (3.4%) tract. Increased rates of infections involved not only the upper (19.0%) and lower (0.3%) respiratory tract, but also the urogenital system (3.6%) and the skin (4.6%). Isolated cases of grade 3 to 4 AEs have been reported, including myocardial infarction, hypertensive urgencies, cellulitis, rhabdomyolysis, neutropenia and high elevation of creatinine kinase. No fatal outcomes were reported. AEs reported with topical formulation included scalp irritation and folliculitis.<\/jats:p><jats:p>The main limit of this review is the lack of data related to postmarketing surveillance, which should be maintained on a long\u2010term basis.<\/jats:p>","DOI":"10.1111\/jdv.19090","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T08:20:17Z","timestamp":1680596417000},"page":"1535-1546","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Adverse events in patients treated with Jak\u2010inhibitors for alopecia areata: A systematic review"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3026-2434","authenticated-orcid":false,"given":"Andrea","family":"Sechi","sequence":"first","affiliation":[{"name":"Dermatology Unit San Bortolo Hospital  Vicenza Italy"},{"name":"Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna Policlinico S'Orsola  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4655-2030","authenticated-orcid":false,"given":"Junhyuk","family":"Song","sequence":"additional","affiliation":[{"name":"Dermatology Unit San Bortolo Hospital  Vicenza Italy"},{"name":"Faculty of Medicine and Surgery, Department of Medicine DIMED University of Padua  Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0250-5750","authenticated-orcid":false,"given":"Massimo","family":"Dell'Antonia","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences and Public Health University of Cagliari  Cagliari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-6086","authenticated-orcid":false,"given":"Kristine","family":"Heidemeyer","sequence":"additional","affiliation":[{"name":"Dermatology Unit San Bortolo Hospital  Vicenza Italy"},{"name":"Department of Dermatology, Bern University Hospital Clinic for Dermatology Inselspital  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6537-9689","authenticated-orcid":false,"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna Policlinico S'Orsola  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3981-1527","authenticated-orcid":false,"given":"Michela","family":"Starace","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna Policlinico S'Orsola  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Naldi","sequence":"additional","affiliation":[{"name":"Dermatology Unit San Bortolo Hospital  Vicenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"e_1_2_10_2_1","first-page":"397","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Villasante Fricke AC","year":"2015","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08883-0"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.1142"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950450"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S309215"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S172638"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.05.027"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15489"},{"key":"e_1_2_10_10_1","unstructured":"European Medicine Agency.Olumiant."},{"key":"e_1_2_10_11_1","unstructured":"US Food and Drug Administration.Janus kinase (JAK) inhibitors: drug safety communication \u2013 FDA requires warnings about increased risk of serious heart\u2010related events cancer blood clots and death.https:\/\/www.fda.gov\/safety\/medical\u2010product\u2010safety\u2010information\/janus\u2010kinase\u2010jak\u2010inhibitors\u2010drug\u2010safety\u2010communication\u2010fda\u2010requires\u2010warnings\u2010about\u2010increased\u2010risk"},{"key":"e_1_2_10_12_1","unstructured":"US Food and Drug Administration.FDA approves first systemic treatment for alopecia Areata.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010systemic\u2010treatment\u2010alopecia\u2010areata"},{"key":"e_1_2_10_13_1","unstructured":"European Medicine Agency.EMA starts safety review of Janus kinase inhibitors for inflammatory disorders."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10777-w"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.050"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.3.701"},{"key":"e_1_2_10_18_1","first-page":"755","article-title":"Smolen JS incidence rate and characterization of herpes zoster in patients with moderate\u2010to\u2010severe rheumatoid arthritis: an update from baricitinib clinical studies","volume":"78","author":"Chen YCY","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221276"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16316"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15361"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02281-4"},{"key":"e_1_2_10_24_1","volume-title":"Olumiant, package insert, Indianapolis","year":"2022"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.006"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14422"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14855"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.02.071"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.031"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13836"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.02.027"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15346"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000780"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16342"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.045"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.12.008"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.891434"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.2036"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20419"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13966"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2019.3668"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13118"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.080"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12844"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1159\/000494613"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_21_18"},{"issue":"7","key":"e_1_2_10_48_1","first-page":"800","article-title":"Successful treatment of severe alopecia Areata with Oral or topical Tofacitinib","volume":"17","author":"Cheng MW","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.032"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.043"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.027"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0001"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.007"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T01:32:01Z","timestamp":1692235921000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/jdv.19090"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19090","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"2022-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}